Advanced search
Add to list

Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM)

(2018) JOURNAL OF CLINICAL ONCOLOGY. 36(15, suppl.).
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Van Droogenbroeck, Jan, et al. “Randomized, Open-Label, Phase 2/3 Study of Daratumumab (DARA) with or without JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma (RRMM).” JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 15, suppl., 2018, doi:10.1200/JCO.2018.36.15_suppl.TPS8057.
APA
Van Droogenbroeck, J., Vlummens, P., Lavi, N., Wu, K. L., Fu, J., Feng, H., … Cohen, Y. (2018). Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM). JOURNAL OF CLINICAL ONCOLOGY, 36(15, suppl.). https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS8057
Chicago author-date
Van Droogenbroeck, Jan, Philip Vlummens, Noa Lavi, Ka Lung Wu, Jiayu Fu, Huaibao Feng, Robin L Carson, Wendy Crist, Jordan Schecter, and Yael Cohen. 2018. “Randomized, Open-Label, Phase 2/3 Study of Daratumumab (DARA) with or without JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma (RRMM).” In JOURNAL OF CLINICAL ONCOLOGY. Vol. 36. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS8057.
Chicago author-date (all authors)
Van Droogenbroeck, Jan, Philip Vlummens, Noa Lavi, Ka Lung Wu, Jiayu Fu, Huaibao Feng, Robin L Carson, Wendy Crist, Jordan Schecter, and Yael Cohen. 2018. “Randomized, Open-Label, Phase 2/3 Study of Daratumumab (DARA) with or without JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma (RRMM).” In JOURNAL OF CLINICAL ONCOLOGY. Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.TPS8057.
Vancouver
1.
Van Droogenbroeck J, Vlummens P, Lavi N, Wu KL, Fu J, Feng H, et al. Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM). In: JOURNAL OF CLINICAL ONCOLOGY. 2018.
IEEE
[1]
J. Van Droogenbroeck et al., “Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM),” in JOURNAL OF CLINICAL ONCOLOGY, 2018, vol. 36, no. 15, suppl.
@inproceedings{8600149,
  articleno    = {{abstract TPS8057}},
  author       = {{Van Droogenbroeck, Jan and Vlummens, Philip and Lavi, Noa and Wu, Ka Lung and Fu, Jiayu and Feng, Huaibao and Carson, Robin L and Crist, Wendy and Schecter, Jordan and Cohen, Yael}},
  booktitle    = {{JOURNAL OF CLINICAL ONCOLOGY}},
  issn         = {{0732-183X}},
  language     = {{eng}},
  number       = {{15, suppl.}},
  title        = {{Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM)}},
  url          = {{http://doi.org/10.1200/JCO.2018.36.15_suppl.TPS8057}},
  volume       = {{36}},
  year         = {{2018}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: